<?xml version="1.0" encoding="UTF-8"?>
<results title="testTrace">
 <result pre="rapidly spreading infection. Frontline healthcare workers are succumbing to the" exact="infection" post="in their efforts to save lives. There is an"/>
 <result pre="autophagy system. Here, we propose trehalose as a potential preventative" exact="treatment" post="for SARS-CoV-2 infection and transmission. trehalose SARS-CoV-2 COVID-19 prophylaxis"/>
 <result pre="we propose trehalose as a potential preventative treatment for SARS-CoV-2" exact="infection" post="and transmission. trehalose SARS-CoV-2 COVID-19 prophylaxis autophagy fig-count: table-count:"/>
 <result pre="up with the influx of COVID-19 patients in need of" exact="treatment" post="and hospitalization. An increasing concern is the detrimental impact"/>
 <result pre="there is no known U.S. Food and Drug Administration (FDA)-approved" exact="treatment" post="that can effectively control SARS-CoV-2 infection and transmission. This"/>
 <result pre="and Drug Administration (FDA)-approved treatment that can effectively control SARS-CoV-2" exact="infection" post="and transmission. This review aims to propose trehalose as"/>
 <result pre="This review aims to propose trehalose as a prospective prophylactic" exact="treatment" post="for COVID-19 containment. Trehalose (Î±,Î±-trehalose), a naturally occurring sugar,"/>
 <result pre="Altogether, these studies support the feasibility and safety of trehalose" exact="treatment" post="for the prevention of SARS-CoV-2 infection and transmission. Since"/>
 <result pre="and safety of trehalose treatment for the prevention of SARS-CoV-2" exact="infection" post="and transmission. Since 1925, several studies aimed to understand"/>
 <result pre="autophagy independent of mTOR (14). In mammalian cell cultures, trehalose" exact="treatment" post="can enhance the clearance of denatured huntingtin and denatured"/>
 <result pre="has shown that trehalose can restore autophagy impaired by HIV" exact="infection" post="in peripheral blood mononuclear cells (PBMCs) in vitro (Table"/>
 <result pre="but autophagy induction impaired antiviral function against human rhinovirus (HRV)" exact="infection" post="(36) (Table 1). Table 1 Summary of antiviral effects"/>
 <result pre="reduced HIV-1 in PBMCs from healthy donor Trehalose ex vivo" exact="treatment" post="reduced HIV-1 in HIV patient PBMCs 100 mM (32)"/>
 <result pre="chloroquine (CQ) or trehalose is of great importance in the" exact="treatment" post="of viral diseases (41). In regard to this, coronaviruses"/>
 <result pre="were to isolate those infected in their household and promote" exact="social distancing" post="(45, 46). However, in light of the continuously increasing"/>
 <result pre="Potential therapies that are being investigated and developed for the" exact="treatment" post="and management of COVID-19 now comprise of numerous antiviral"/>
 <result pre="U.S. FDA has authorized emergency use of remdesivir for the" exact="treatment" post="of COVID-19 (53). Lopinavir/Ritonavir, an HIV protease inhibitor, was"/>
 <result pre="of the patients had to be removed early in the" exact="treatment" post="due to adverse side effects (55). New triple antiviral"/>
 <result pre="therapy combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the" exact="treatment" post="of mild to moderate COVID-19 patients was safe and"/>
 <result pre="to moderate COVID-19 patients was safe and superior to lopinavir-ritonavir" exact="treatment" post="alone in alleviating symptoms, shortening the duration of viral"/>
 <result pre="evidence moved CQ into the clinical trial phase for the" exact="treatment" post="of COVID-19. The FDA approved the emergency use of"/>
 <result pre="therapy has been used in randomized clinical trials for the" exact="treatment" post="of influenza (63). The French Ministry of Health approved"/>
 <result pre="influenza infection, the viral shedding phase peaks 2â€&quot;3 days after" exact="infection" post="(68). A meta-analysis of randomized controlled trials of oseltamivir"/>
 <result pre="of randomized controlled trials of oseltamivir (Tamiflu) indicates that early" exact="treatment" post="of the infection accelerated clinical symptom alleviation and reduced"/>
 <result pre="trials of oseltamivir (Tamiflu) indicates that early treatment of the" exact="infection" post="accelerated clinical symptom alleviation and reduced the risks of"/>
 <result pre="lung caused by a â€œcytokine stormâ€� in patients with COVID-19" exact="infection" post="(clinicalTrials.gov, NCT 04315298) and Swedish Orphan Biovitrum (SOBI) also"/>
 <result pre="to reduce hyper-inflammation and respiratory distress in patients with COVID-19" exact="infection" post="(clinicalTrials.gov, NCT 04324021). Overall, there are more clinical research"/>
 <result pre="FDA approval, trehalose merits immediate evaluation as a promising preventative" exact="treatment" post="for COVID-19. Several non-specific antiviral drugs are undergoing clinical"/>
 <result pre="and faster diagnostic tests are still underway, as a timely" exact="diagnosis" post="is key to the management of COVID-19 (75). There"/>
 <result pre="date, the immediate interventions for SARS-CoV-2 transmission have centered on" exact="contact tracing," post="quarantine, and social distancing. Adaptation of these physical distancing"/>
 <result pre="for SARS-CoV-2 transmission have centered on contact tracing, quarantine, and" exact="social distancing." post="Adaptation of these physical distancing measures to mitigate the"/>
 <result pre="on contact tracing, quarantine, and social distancing. Adaptation of these" exact="physical distancing" post="measures to mitigate the pandemic has managed to flatten"/>
 <result pre="3 years (83). Mathematical modeling of various scenarios with one-time" exact="social distancing" post="measures has simulated a resurgence of infection when social"/>
 <result pre="with one-time social distancing measures has simulated a resurgence of" exact="infection" post="when social distancing measures were lifted (83). Thus, additional"/>
 <result pre="social distancing measures has simulated a resurgence of infection when" exact="social distancing" post="measures were lifted (83). Thus, additional methods that circumnavigate"/>
 <result pre="measures were lifted (83). Thus, additional methods that circumnavigate enforced" exact="social distancing" post="and shutting down the economy are needed. Alternatively, the"/>
 <result pre="immune. We propose trehalose as a practical and affordable safe" exact="treatment" post="for the prevention and containment of COVID-19. Trehalose could"/>
 <result pre="SARS-CoV-2 during the presymptomatic stage of the infection; therefore, trehalose" exact="treatment" post="as a prophylactic approach would be advisable (88, 89)."/>
 <result pre="approach would be advisable (88, 89). Family members of patients" exact="testing" post="positive for COVID-19 will be recommended to undergo trehalose"/>
 <result pre="testing positive for COVID-19 will be recommended to undergo trehalose" exact="treatment" post="and stay at home in self-quarantine, as the secondary"/>
 <result pre="their education system, and the long term effects of SARS-CoV-2" exact="infection" post="are still unknown in children. Clinical studies on the"/>
 <result pre="By treating healthy adults with trehalose, population-level resistance to the" exact="infection" post="will block the chain of transmission. As a result"/>
 <result pre="be drastically reduced as they are indirectly protected from the" exact="infection" post="(Figure 2) (95). Furthermore, trehalose can activate TFEB and"/>
 <result pre="a second wave of COVID-19 cases. We believe that this" exact="treatment" post="strategy can be more beneficial to countries that do"/>
 <result pre="the resources to conduct antiviral clinical trials. Figure 2 Trehalose" exact="treatment" post="for fast SARS-CoV-2 containment. Treating healthy adults and asymptomatic"/>
 <result pre="ventilation), while other autophagy activations inhibited ARDS (96). Therefore, trehalose" exact="treatment" post="would be inappropriate to treat intensive care patients with"/>
 <result pre="diseases society of America on the management of influenza, early" exact="treatment" post="with antiviral medications attenuates symptoms and risk complications. In"/>
 <result pre="In vitro studies on the effects of trehalose on SARS-CoV-2" exact="infection" post="still need to be investigated since some type of"/>
 <result pre="highjack the autophagy system and enhance their replication with trehalose" exact="treatment" post="(e.g., HRV) (36). Once confirming the effectivity of trehalose,"/>
 <result pre="autophagy; however, it is not a good strategy for viral" exact="infection" post="as previously reported (99). Thus, we do not recommend"/>
 <result pre="(99). Thus, we do not recommend fasting as a prophylactic" exact="treatment" post="for COVID-19. Rapamycin, a representative mTOR-dependent autophagy activator, has"/>
 <result pre="adverse effect that may make it inadequate as a prophylactic" exact="treatment" post="of SARS-CoV-2 (15). As SARS-CoV-2 continues to expand globally,"/>
 <result pre="understanding of its impact on disparate communities. The proposed trehalose" exact="treatment" post="could potentially protect those unable to seek more costly"/>
 <result pre="34.BelzileJPSabalzaMCraigMClarkEMorelloCSSpectorDH. Trehalose, an mTOR-independent inducer of autophagy, inhibits human cytomegalovirus" exact="infection" post="in multiple cell types. J Virol. (2016) 90:1259â€&quot;77. 10.1128/JVI.02651-1526559848"/>
 <result pre="COVID-19. Lancet Infect Dis. (2020) 20:631â€&quot;3. 10.1016/S1473-3099(20)30190-032213329 46.MalayDS. COVID-19, pandemic," exact="social distancing." post="J Foot Ankle Surg. (2020) 59:447â€&quot;8. 10.1053/j.jfas.2020.03.01032354499 47.AyitteyFKAyitteyMKChiweroNBKamasahJSDzuvorC. Economic"/>
 <result pre="Triple combination of inferferon beta-1b, lopinavir-ritonavir, and ribavirin in the" exact="treatment" post="of patients admitted to hospital with COVID-19: an open-label,"/>
 <result pre="acidification by chloroquine analogs as a promising strategy for the" exact="treatment" post="of emerging viral diseases. Pharmacol Res Perspect. (2017) 5:e00293."/>
 <result pre="(2014) 9:e91293. 10.1371/journal.pone.009129324632748 64.GautretPLagierJCParolaPHoangVTMeddebLMailheMet al.. Hydroxychloroquine and azithromycin as a" exact="treatment" post="of COVID-19: results of an open-label non-randomized clinical trial."/>
 <result pre="of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients" exact="testing" post="positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol. (2020)."/>
 <result pre="China. Lancet. (2020) 395:497â€&quot;506. 10.1016/S0140-6736(20)30183-531986264 68.CarratFVerguEFergusonNMLemaitreMCauchemezSLeachSet al.. Time lines of" exact="infection" post="and disease in human influenza: a review of volunteer"/>
 <result pre="challenge studies. Am J Epidemiol. (2008) 167:775â€&quot;85. 10.1093/aje/kwm37518230677 69.DobsonJWhitleyRJPocockSMontoAS. Oseltamivir" exact="treatment" post="for influenza in adults: a meta-analysis of randomised controlled"/>
 <result pre="10.1093/cid/ciy866 71.ZhangWZhaoYZhangFWangQLiTLiuZet al.. The use of anti-inflammatory drugs in the" exact="treatment" post="of people with severe coronavirus disease 2019 (COVID-19): the"/>
</results>
